Previous 10 |
Pear Therapeutics announces the acquisition and license of two digital therapeutic assets designed to treat patients with a range of depression symptoms Pear is developing a prescription digital therapeutic (PDT) candidate that may be developed for use alone or in combin...
Expansion of Crossroads’s existing initiative with Pear’s prescription digital therapeutics (PDTs), reSET ® and reSET-O ® , has the potential to reach thousands of additional patients per month on their recovery journey across Kentucky, New Jersey, Pe...
After a ~15.9% rise on Wednesday, the shares of Pear Therapeutics (PEAR +18.0%) are trading higher once again in the morning hours after LJ10 LLC disclosed a passive investment in the company. According to a regulatory filing on Wednesday, the limited-liability company has indicated...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, trader! It’s time to kick off another busy day of trading with the biggest pre-market stock movers for Thursday! Source: Shutterstock We’ve got SPAC mergers, earnings reports, FDA updates...
Palantir's Q3 showed solid growth continuing, with strengths in multiple key metrics supporting long-term growth targets, as well as new SPAC investments. Investments in these SPACs have reached $379.5 million, while current share values are ~$317 million, for a -19% return. Many ...